Stock NYXH NYXOAH SA
Add to a list
To use this feature you must be a member
Log inSign up

Nyxoah SA Stock

Equities

NYXH

BE0974358906

Advanced Medical Equipment & Technology

Market Closed - Euronext Bruxelles
Other stock markets
 11:37:01 2024-04-26 am EDT 		5-day change 1st Jan Change
9.6 EUR +2.78% Intraday chart for Nyxoah SA +4.35% +125.35%
Apr. 12 Nyxoah Names New Chief Medical Officer MT
Apr. 12 Nyxoah S.A. Appoints Maurits Boon as Chief Medical Officer CI

Financials

Sales 2024 * 8.78M 9.39M Sales 2025 * 36.18M 38.69M Capitalization 268M 286M
Net income 2024 * -61M -65.23M Net income 2025 * -69M -73.79M EV / Sales 2024 * 24.5 x
Net cash position 2024 * 52.9M 56.57M Net Debt 2025 * 16.5M 17.64M EV / Sales 2025 * 7.86 x
P/E ratio 2024 *
-4.43 x
P/E ratio 2025 *
-4.79 x
Employees 147
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.79%
More Fundamentals * Assessed data

Chart Nyxoah SA

Dynamic Chart

Latest news about Nyxoah SA

Nyxoah Names New Chief Medical Officer MT
Nyxoah S.A. Appoints Maurits Boon as Chief Medical Officer CI
Nyxoah Appoints Maurits Boon as Chief Medical Officer MT
Top Premarket Decliners MT
Nyxoah Partners With Medical Association to Lobby Insurers and Regulators MT
Global markets live: Super Micro Computer, Boeing, Vale, Tesla, Nvidia, Intel, Nasdaq... Our Logo
Stifel Adjusts Nyxoah's Price Target to $27 From $20, Keeps Buy Rating MT
HC Wainwright Raises Nyxoah Price Target to $22 From $18, Maintains Buy Rating MT
Nyxoah Says US Study of Genio System for Sleep Apnea Reaches Primary Endpoints MT
Oppenheimer Adjusts Nyxoah Price Target to $20 From $17, Maintains Outperform Rating MT
Piper Sandler Raises Nyxoah's Price Target to $20 From $15, Maintains Overweight Rating MT
Oppenheimer Adjusts Nyxoah Price Target to $17 From $12, Maintains Outperform Rating MT
Nyxoah S.A. Provides Earnings Guidance for the First Quarter of 2024 CI
Transcript : Nyxoah S.A., Q4 2023 Earnings Call, Mar 05, 2024
Nyxoah S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
More news

Latest transcript on Nyxoah SA

Logo Nyxoah SA
Nyxoah S.A., Q4 2023 Earnings Call, Mar 05, 2024
More transcripts

Analyst Recommendations on Nyxoah SA

Stifel Adjusts Nyxoah's Price Target to $27 From $20, Keeps Buy Rating MT
HC Wainwright Raises Nyxoah Price Target to $22 From $18, Maintains Buy Rating MT
Oppenheimer Adjusts Nyxoah Price Target to $20 From $17, Maintains Outperform Rating MT
Piper Sandler Raises Nyxoah's Price Target to $20 From $15, Maintains Overweight Rating MT
Oppenheimer Adjusts Nyxoah Price Target to $17 From $12, Maintains Outperform Rating MT
More recommendations

Press releases Nyxoah SA

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer GL
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation GL
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation AQ
Nyxoah : Annual Report 2023 PU
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints GL
More press releases

News in other languages on Nyxoah SA

Brussel met winst het weekend in
Bel20 sluit lager ondanks koerswinst UCB
Argenx helpt Brussel aan groen slot
Brussel sluit mooi hoger
Bel20 bouwt winst uit met nieuw record voor UCB
More news

Quotes and Performance

1 day+2.78%
1 week+4.35%
Current month-21.95%
1 month-22.27%
3 months+13.21%
6 months+63.82%
Current year+125.35%
More quotes

Highs and lows

1 week
9.22
Extreme 9.22
10.35
1 month
8.30
Extreme 8.3
12.85
Current year
3.79
Extreme 3.79
17.60
1 year
3.79
Extreme 3.79
17.60
3 years
3.79
Extreme 3.79
30.00
5 years
3.79
Extreme 3.79
30.00
10 years
3.79
Extreme 3.79
30.00
More quotes

Managers and Directors - Nyxoah SA

Managers TitleAgeSince
Olivier Taelman CEO
 Chief Executive Officer 54 19-06-30
Robert Taub FOU
 Founder 78 09-07-14
Loïc Moreau DFI
 Director of Finance/CFO - 21-12-31
Members of the board TitleAgeSince
Kevin Rakin BRD
 Director/Board Member 63 16-06-28
Robert Taub FOU
 Founder 78 09-07-14
Jürgen Hambrecht BRD
 Director/Board Member 77 15-12-31
More insiders

Quotes

Date Price Change Volume
24-04-26 9.6 +2.78% 17 475
24-04-25 9.34 -4.69% 8,309
24-04-24 9.8 0.00% 12,036
24-04-23 9.8 -2.49% 33,253
24-04-22 10.05 +9.24% 54,904

Real-time Euronext Bruxelles, April 26, 2024 at 11:37 am EDT

More quotes

Company Profile

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah SA's innovative solution platform is based on the Genio® system, a CE-Mark validated, user-centered neurostimulation therapy for obstructive sleep apnea, the world's most common sleep disordered breathing condition.
Sector
Advanced Medical Equipment & Technology
Calendar
2024-05-14 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Nyxoah SA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
9.34 EUR
Average target price
15.5 EUR
Spread / Average Target
+65.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
NYXOAH SA Stock Nyxoah SA
+125.35% 287M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.16% 218B
DANAHER CORPORATION Stock Danaher Corporation
+7.12% 182B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.36% 132B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.88% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.10% 52.98B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 47.59B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.77% 39.96B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.45% 39.22B
RESMED, INC. Stock ResMed, Inc.
+26.72% 26.94B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. NYXH Stock